Sonion Announces New CEO & President: Niels Svenningsen

Niels Svenningsen to Further Develop Sonion's Position in the Current Market and Develop New Product

Sonion today announces the appointment of Niels Svenningsen as CEO & President of the Sonion Group. Niels Svenningsen was most recently President of Northern Europe in Schneider Electric and brings a wealth of commercial and management experience acquired in the IT and technology sectors. He will start in his new position on March 1st, 2020.

“We look very much forward to welcoming Niels. He brings an extensive commercial and general management experience to Sonion. We expect Niels to further develop our strong position of Sonion in the current market and develop new products to serve the potential of adjacent markets.” says Walther Thygesen, Chairman of the Sonion Board.

Niels Svenningsen (55 years old) was President of Northern Europe in Schneider Electric (2015-2019) and before that CEO of GN NetCom (2013-2015). Niels also has extensive experience with Sales and Marketing from large IT companies such as Hitachi Data Systems (2007-2013; Senior Vice President & General Manager EMEA 2011-2013), Hewlett Packard (Managing Director, Enterprise & Major Accounts 2002-2004; Sales Director 1996-2000) and IBM Denmark (1988-1996).

”I am very happy to be joining Sonion. This is a global company, well run and with a lot of potential, operating in an attractive market for high-tech medical components. I look forward to – together with the Sonion management team – taking Sonion further on its growth journey and exploring new attractive opportunities on the market.” says Niels Svenningsen.

Sonion is a global leader in the development and manufacturing of micro acoustic and micro mechanical solutions for hearing instruments, high-end hearables, and in-ear earphones. Sonion is owned by Novo Holdings A/S, the holding company within the Novo Group that manages the assets of the Novo Nordisk Foundation.

SourceSonion

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”